Qiagen and Agilent both had strong stock gains during the past week, leading the BioCommerce Week Index of multi-platform molecular biology tool firms. Qiagen shares rose 10 percent, though the reason for the upward movement is not readily apparent. Agilent's shares climbed 9.78 percent, due largely to a report in the Wall Street Journal that the firm's semiconductor business could be sold as early as late this week for as much as $2.5 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.